|
Market Closed -
Nasdaq
04:00:00 31/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 144.85 USD | +0.35% |
|
+4.64% | +65.85% |
| 10-23 | UK approves J&J's oral psoriasis pill | RE |
| 10-12 | UBS Initiates Coverage on Protagonist Therapeutics With Buy Rating, $184 Price Target | MT |
| Market Cap | 9.37B 8.39B 7.72B 7B 13.08B 890B 13.32B 92.08B 36.96B 468B 35.18B 34.43B 1,476B | P/E 2026 * |
31.2x | P/E 2027 * | -478x |
|---|---|---|---|---|---|
| Enterprise Value | 8.85B 7.92B 7.29B 6.6B 12.34B 840B 12.57B 86.9B 34.89B 442B 33.2B 32.49B 1,393B | EV / Sales 2026 * |
16.1x | EV / Sales 2027 * | 41.2x |
| Free-Float |
97.68% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| PTGX | Delayed | |
CBOE
| PTGX | Real-time | |
|
Tradegate
| PGF | Real-time |
Last Transcript: Protagonist Therapeutics, Inc.
| 1 day | +0.35% | ||
| 1 week | +4.64% | ||
| 1 month | +2.81% | ||
| 3 months | +6.01% | ||
| 6 months | +46.36% | ||
| Current year | +65.85% |
| 1 week | 137.3 |  | 146.44 |
| 1 month | 126.39 | | 152.18 |
| Current year | 77 | | 160.81 |
| 1 year | 75.44 | | 160.81 |
| 3 years | 14.78 | | 160.81 |
| 5 years | 6.91 | | 160.81 |
| 10 years | 4.47 | | 160.81 |
| Manager | Title | Age | Since |
|---|---|---|---|
Dinesh Patel
CEO | Chief Executive Officer | 69 | 01/12/2008 |
Asif Ali
DFI | Director of Finance/CFO | 52 | 18/04/2022 |
Venkat Thalladi
CTO | Chief Tech/Sci/R&D Officer | - | 01/04/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Dinesh Patel
BRD | Director/Board Member | 69 | 01/12/2008 |
Harold Selick
CHM | Chairman | 71 | 19/03/2014 |
William Waddill
BRD | Director/Board Member | 69 | 01/07/2016 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 30/9/26 | Exercice | Chief Financial Officer | 175,887 | 0.2718% | ||
| 10/9/26 | Exercice | Chief Executive Officer | 21,834 | 0.0337% | ||
| 3/9/26 | Don | Chief Executive Officer | -510 | 0.0008% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.35% | +4.64% | +84.24% | +896.22% | 9.37B | |
| -0.62% | -1.87% | +42.87% | +64.15% | 63.77B | |
| +0.35% | +3.20% | +14.40% | +81.76% | 56.37B | |
| +0.53% | +1.96% | +16.24% | +103.35% | 54.62B | |
| -2.81% | -4.31% | +23.50% | +47.83% | 44.06B | |
| -0.33% | -1.93% | +19.28% | +98.80% | 42.11B | |
| +0.55% | +2.31% | +225.14% | +866.21% | 41B | |
| +3.27% | +47.96% | +112.84% | +96.58% | 34.92B | |
| +1.22% | -1.44% | +14.57% | +46.95% | 32.82B | |
| +0.89% | +20.55% | -40.62% | +349.24% | 24.7B | |
| Average | +0.34% | +7.25% | +51.24% | +265.11% | 40.37B | |
| Weighted average by Cap. | +0.18% | +5.42% | +48.83% | +193.38% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 549M 492M 452M 410M 766M 52.13B 780M 5.39B 2.17B 27.42B 2.06B 2.02B 86.48B | 215M 193M 178M 161M 301M 20.46B 306M 2.12B 850M 10.76B 809M 792M 33.94B |
| Net income | 326M 292M 269M 243M 455M 30.97B 464M 3.2B 1.29B 16.29B 1.22B 1.2B 51.38B | -18.36M -16.44M -15.12M -13.7M -25.61M -1.74B -26.09M -180M -72.39M -917M -68.89M -67.42M -2.89B |
| Net Debt | -527M -472M -434M -393M -735M -50.03B -749M -5.18B -2.08B -26.32B -1.98B -1.94B -83B | -494M -443M -407M -369M -690M -46.93B -702M -4.86B -1.95B -24.68B -1.85B -1.82B -77.84B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/10/26 | US$144.85 | +0.35% | 322,566 |
| 29/10/26 | US$144.34 | +1.55% | 325,557 |
| 28/10/26 | US$142.14 | +0.72% | 318,458 |
| 27/10/26 | US$141.12 | +0.57% | 865,925 |
| 26/10/26 | US$140.32 | +1.37% | 823,277 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PTGX Stock
Select your edition
All financial news and data tailored to specific country editions
